Cargando…

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge

Although immune checkpoint inhibitors (ICIs) have dramatically revolutionized the field of oncology over the last decade, severe immune-related adverse events (irAEs) are potentially life-threatening. In comparison with toxicities involving the skin, gastrointestinal tract and endocrine system, neph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catalano, Martina, Roviello, Giandomenico, Galli, Ilaria Camilla, Santi, Raffaella, Nesi, Gabriella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807763/ https://www.ncbi.nlm.nih.gov/pubmed/36606052 http://dx.doi.org/10.3389/fmed.2022.1014257

Ejemplares similares

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Immune combinations and complete response: a new hope for metastatic renal cell carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Inflammation in Urological Malignancies: The Silent Killer
por: Catalano, Martina, et al.
Publicado: (2023)

Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity
por: Moss, Emily M., et al.
Publicado: (2022)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Gender and Advanced Urothelial Cancer: Outcome, Efficacy and Toxicity following Chemotherapy
por: Becattini, Lucrezia, et al.
Publicado: (2022)

Serum sodium levels associate with recovery of kidney function in immune checkpoint inhibitor nephrotoxicity
por: Tampe, Désirée, et al.
Publicado: (2023)

Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
por: Cosso, Federica, et al.
Publicado: (2023)

DNA repair deficiency as circulating biomarker in prostate cancer
por: Catalano, Martina, et al.
Publicado: (2023)

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
por: Sobhani, Navid, et al.
Publicado: (2021)

Nephrotoxicity of Immune Checkpoint Inhibitors: Acute Kidney Injury and Beyond
por: Tinawi, Mohammad, et al.
Publicado: (2020)

Compartmentalization of Intrarenal Programmed Cell Death Protein 1-Ligand 1 and Its Receptor in Kidney Injury Related to Immune Checkpoint Inhibitor Nephrotoxicity
por: Tampe, Désirée, et al.
Publicado: (2022)

Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
por: Sobhani, Navid, et al.
Publicado: (2022)

Editorial: Microbiota and metabolites in cancer immunotherapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Angiosarcoma of the Urinary Bladder Following Radiotherapy: Report of a Case and Review of the Literature
por: Cito, Gianmartin, et al.
Publicado: (2021)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Current Knowledge of the Potential Links between Inflammation and Prostate Cancer
por: Cai, Tommaso, et al.
Publicado: (2019)

Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers
por: Kaźmierczak-Siedlecka, Karolina, et al.
Publicado: (2021)

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
por: Mamlouk, Omar, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?
por: Mortensen, Line Aas, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors and the Heart
por: Mocan-Hognogi, Diana Larisa, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Induced Lymphocytic Esophagitis
por: Amin, Shefali, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis
por: Pagan, Andrea, et al.
Publicado: (2020)

Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis
por: Verma, Neha, et al.
Publicado: (2021)

Isolated Neutropenia Due to Immune Checkpoint Inhibitors
por: Jalil, Ahmad, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis
por: Khan, Jaffar, et al.
Publicado: (2021)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge
por: Miao, Jing, et al.
Publicado: (2022)

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
por: Yu, Jiahui, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
por: Nakamura, Yoshiyuki
Publicado: (2019)

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders
por: Coureau, Michelle, et al.
Publicado: (2020)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Shen, Pan, et al.
Publicado: (2021)

Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
por: Poggi, Alessandro, et al.
Publicado: (2021)

FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
por: Catalano, Martina, et al.
Publicado: (2020)

Liquid biopsy in colorectal cancer: No longer young, but not yet old
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9a1l26bv7fuiqnk3puga04akil